Coronary intervention with a heparin-coated stent and aspirin only

Peter N. Ruygrok, Kui Hian Sim, Charles Chan, Otte Juniarto Rachman, Jeffrey D. Adipranoto, Hanafi BinartoTrisnohadi, James T. Stewart, Nik Ahmad, Koon How Mak, Muhammad Yusak, Iwan Boestan, Teguh Santoso Sukamto, Harry Suryapranata

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Objectives. To determine the safety and efficacy of a post-stenting anti-platelet regimen of aspirin - without additional ticlopidine or clopidogrel - after successful heparin-coated stent implantation. Methods. A prospective, non-randomized, multi-center pilot study of patients undergoing percutaneous coronary intervention, including those with acute coronary syndromes and small vessels with one-month clinical follow-up, was undertaken. Patients received a heparin-coated stent and were treated with aspirin only. Results. Over a period of 6 months, a total of 122 patients were recruited in 6 centers. Their mean age was 57.2 ± 10.0 years, 79% were male and 31% had unstable angina. Most (75%) had single-vessel disease, predominantly of the left anterior descending artery (51%), with a mean reference diameter of 2.44 mm ± 0.44 mm at baseline and 2.48 ± 0.41 mm post stenting. At a 1-month clinical follow-up, no major adverse cardiovascular events (including subacute stent thrombosis) had occurred. Five patients were readmitted to hospital for symptoms unrelated to the interventional procedure. Conclusions. Heparin-coated stent implantation using an antiplatelet regimen of aspirin only, appears to be safe and feasible. A randomized trial of a larger number of patients appears warranted.

Original languageEnglish
Pages (from-to)439-441
Number of pages3
JournalJournal of Invasive Cardiology
Issue number8
Publication statusPublished - 1 Aug 2003


  • Angioplasty
  • Heparin
  • Stents


Dive into the research topics of 'Coronary intervention with a heparin-coated stent and aspirin only'. Together they form a unique fingerprint.

Cite this